Johansson Susanne, Engström Gunnel, Winberg Gösta, Hinkula Jorma, Wahren Britta
Microbiology and Tumor Biology Center, and Swedish Institute for Infectious Disease Control, Karolinska Institutet, Tomtebodavägen 12B, S-171 82 Solna, Sweden.
Vaccine. 2006 May 22;24(21):4572-5. doi: 10.1016/j.vaccine.2005.08.044. Epub 2005 Aug 24.
C57BL/6 and BALB/c mice were immunized with two different plasmids (p91023B and pKCEA66) encoding different forms of the tumor-associated antigen carcinoembryonic antigen (CEA). The wild type form of CEA (p91023B), which is expressed at the cell surface, induces stronger anti-CEA IgG response after DNA-plasmid immunizations than the modified intracellular form of CEA (pKCEA66), which was designed to mount strong cellular responses. Boosting with recombinant CEA (rCEA) increased the anti-CEA IgG response significantly. In the tumor protection model used, where SCID mice are challenged with human tumor cells mixed with splenocytes from immunized mice, both innate and specific immune responses are responsible for the protective effect.
用两种编码不同形式肿瘤相关抗原癌胚抗原（CEA）的不同质粒（p91023B和pKCEA66）对C57BL/6和BALB/c小鼠进行免疫。细胞表面表达的野生型CEA（p91023B）在DNA质粒免疫后诱导的抗CEA IgG反应比经修饰的细胞内形式CEA（pKCEA66）更强，后者旨在引发强烈的细胞反应。用重组CEA（rCEA）加强免疫显著增加了抗CEA IgG反应。在所用的肿瘤保护模型中，即给SCID小鼠接种来自免疫小鼠的脾细胞与人类肿瘤细胞的混合物，先天免疫反应和特异性免疫反应均对保护作用有贡献。
